Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

NANOFLD

Financiado

Nano-Technology Enabled Repositioning of Cannabinoids for Treating NAFLD

Obesity is a catalyst for numerous conditions; the most notable is non-alcoholic fatty liver disease (NAFLD), for which currently no drug therapy has been approved by the FDA and EMA for its treatment. The endocannabinoid (eCB) sy... ver más

30/04/2024

THE HEBREW UNIVERS...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 1 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-04-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2

I+D

Cerrada hace 2 años

0% 100%

1 Participantes

THE HEBREW UNIVERSITY OF JER...

150.00K€ | Lider

Proyectos interesantes

PID2021-127493OB-C21 HERRAMIENTAS TECNOLOGICAS PARA EL CONTROL DEL TRAFICO SISTEM... 183K€ Cerrado

INTESTINANOS Intestinal Lipoidal Nanostructures A Lipid Bridge to Incre... 2M€ Cerrado

PRE2020-094885 OPCIONES TERAPEUTICAS DE LA CICLOOXIGENASA 2 EN LA ENFERMEDA... 99K€ Cerrado

RTI2018-098164-B-I00 MOVIMIENTO DE NANOROBOTS BIOCATALITICOS EN FLUIDOS BIOLOGICO... 218K€ Cerrado

RTI2018-101309-B-C21 SINTESIS Y CARACTERIZACION DE NANOGHOSTS COMO SISTEMAS NOVED... 154K€ Cerrado

PID2021-122714OB-I00 ESTRATEGIA NANOTERAGNOSTICA PARA ATEROSCLEROSIS BASADA EN UN... 138K€ Cerrado

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 19 meses Fecha Inicio: 2022-09-29
Fecha Fin: 2024-04-30

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Obesity is a catalyst for numerous conditions; the most notable is non-alcoholic fatty liver disease (NAFLD), for which currently no drug therapy has been approved by the FDA and EMA for its treatment. The endocannabinoid (eCB) system triggers the development of obesity and its related comorbidities, specifically NAFLD. eCBs, via activating the cannabinoid-1 receptors (CB1Rs) in the liver, increase hepatic glucose production, insulin resistance, and de novo lipogenesis, and decrease fatty acid oxidation. Accordingly, globally-acting CB1R blockers improve these parameters both in rodents and humans. However, owing to their neuropsychiatric side effects, they were withdrawn from the market and are no longer available for clinical use. NANOFLD aims to revive their clinical development and testing by utilizing an innovative nanometric drug delivery system for the hepatic targeting of globally-acting CB1R blockers for treating NAFLD. In the framework of my ERC-StG grant, CaNanoBinoids, my team successfully encapsulated the first-in-class CB1R blocker, rimonabant, in nanoparticles (NPs), tested their stability, efficacy, and potency, and demonstrated their therapeutic potential in ameliorating NAFLD, insulin resistance, and dyslipidemia in mice. To further translate our findings into clinical practice, the present PoC application builds on and expands this avenue of research by achieving several necessary steps including biodistribution, hepatic cellular fate, and PK studies of our novel nanometric drug delivery system. Importantly, we have secured the IP, conducted a specific market assessment, targeted regulatory constraints, implemented a business development plan, consulted with professionals in the field, and developed contacts with industry. When this project is completed, we expect to have introduced a unique innovation to treat NAFLD and its metabolic abnormalities, further promoting the idea to clinically test CB1R blockers encapsulated in NPs against NAFLD.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores